Investigation Report on China's Recombinant Human Thrombopoietin Market, 2019-2023


Description
In recent years, the incidence of thrombopenia in China keeps increasing. Thrombopenia is often seen in hematologic diseases such as primary immune thrombopenia, leukemia and aplastic anemia as well as in connective tissue diseases, liver diseases and tumor chemotherapy. Thrombopenia may also be congenital or drug-induced. Primary immune thrombopenia is a clinically common hemorrhagic disease, accounting for 1/3 of hemorrhagic diseases. The annual incidence of primary immune thrombopenia is 5/100,000 to 10/100,000. The number of patients with thrombopenia in China is increasing by over 100,000 every year. Research shows that 20% to 30% of patients receiving chemotherapy have obvious thrombopenia. The incidence of thrombopenia is 81.80% among patients receiving single-agent carboplatin chemotherapy, 58.20% among patients receiving carboplatin combination chemotherapy, 64.40% among patients receiving gemcitabine chemotherapy and 59.30% among patients receiving paclitaxel chemotherapy.
Using thrombopoietin such as Recombinant Human Thrombopoietin is one of the ways to treat thrombopenia. In 2005, Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. (trade name: TPIAO) was approved to be sold in China. By Aug. 2019, it is the only approved Recombinant Human Thrombopoietin product on the Chinese market.
In China, Recombinant Human Thrombopoietin applies to the treatment of patients with thrombopenia (platelet count < 50?109/L) caused by solid tumor chemotherapy when doctors regard it necessary to increase platelet count. It is also used to assist the treatment of patients who have idiopathic thrombocytopenic purpura with platelet count below 20?109/L when glucocorticoids do not work. It is only applied to patients with thrombopenia and patients facing the increasing risk of bleeding. It is not used to increase platelet count to the normal level.
According to CRI's market survey, the sales value of Recombinant Human Thrombopoietin kept rising after the drug was launched in China. In 2017, it reached CNY 523 million, representing a CAGR of 27.90% from 2013 to 2017.
CRI expects that as the number of patients with thrombopenia increases in China, the demand for Recombinant Human Thrombopoietin will also increase. Considering the high growth rate of the Recombinant Human Thrombopoietin market, Recombinant Human Thrombopoietin products by other enterprises will probably be approved to be launched in China in the next few years.
Table of Contents
1 Relevant Concepts of Recombinant Human Thrombopoietin
1.1 Indications for Recombinant Human Thrombopoietin
1.2 Development of Recombinant Human Thrombopoietin in China
1.3 Patents and Government Approval on Recombinant Human Thrombopoietin in China

2 Sales of Recombinant Human Thrombopoietin in China, 2013-2017
2.1 Sales Value of Recombinant Human Thrombopoietin
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Recombinant Human Thrombopoietin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Recombinant Human Thrombopoietin by Dosage Form in China, 2013-2017
2.3.1 Injections
2.3.2 Development Trend of Dosage Forms

3 Analysis on Major Manufacturer of Recombinant Human Thrombopoietin in China, 2013-2017
3.1 Market Share of Major Manufacturer of Recombinant Human Thrombopoietin
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Shenyang Sunshine Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. in China

4 Prices of Recombinant Human Thrombopoietin in China, 2017-2018
4.1 Shenyang Sunshine Pharmaceutical Co., Ltd. (TPIAO)
4.2 Price Trend of Recombinant Human Thrombopoietin

5 Prospect of China's Recombinant Human Thrombopoietin Market, 2019-2023
5.1 Factors Influencing Development of China's Recombinant Human Thrombopoietin Market
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Selected Charts
Chart Patents on Recombinant Human Thrombopoietin in China
Chart Government Approval on Recombinant Human Thrombopoietin in China
Chart Sales of Recombinant Human Thrombopoietin in China, 2013-2017
Chart Sales Value of Recombinant Human Thrombopoietin in Parts of China, 2013-2017
Chart Sales Volume of Recombinant Human Thrombopoietin in China, 2013-2017
Chart Sales Volume of Recombinant Human Thrombopoietin in Parts of China, 2013-2017
Chart Sales Value of Recombinant Human Thrombopoietin Injections in China, 2013-2017
Chart Sales Volume of Recombinant Human Thrombopoietin Injections in China, 2013-2017
Chart Market Share of Manufacturer of Recombinant Human Thrombopoietin by Sales Value in China, 2013-2017
Chart Sales Value of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. in China, 2013-2017
Chart Prices of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. (TPIAO) in Parts of China, 2017-2018
Chart Forecast on Sales Value of Recombinant Human Thrombopoietin in China, 2019-2023


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by China Research and Intelligence

Investigation Report on China's Finasteride Market, 2019-2023

Description The prostate is a male-specific gonadal organ. Benign prostatic hyperplasia (BPH) is the most common benign disease among the causes of urination disorder in middle-aged and elderly men. Epidemiologically, the incidence of BPH increases w...

Investigation Report on China's Prothrombin Complex Concentrate (PCC) Market, 2019-2023

Description Hemophilia is an X-linked recessive hemorrhagic disease. It is classified into hemophilia A, a deficiency in clotting factor VIII and hemophilia B, a deficiency in clotting factor IX. Both hemophilia A and hemophilia B are caused by gene ...

Investigation Report on China's Pegaspargase Market, 2019-2023

Description According to the data released by China?s National Health Commission in Oct. 2018, the incidence of childhood leukemia in Chinese children under 15 is about 4/100,000 to 5/100,000, and the number of childhood leukemia patients under 18 ol...

Investigation Report on China's Basiliximab Market, 2019-2023

Description In China, 10.80% or about 150 million people have chronic kidney disease, and over 3 million of them have end-stage renal disease, i.e. uremia. According to CRI, the incidence of chronic kidney disease in China stays at a high level in re...

Investigation Report on China's Diclofenac Market, 2019-2023

Description Rheumatoid arthritis is a common frequently-occurring disease. According to the 2018 Chinese Guideline for the Diagnosis and Treatment of Rheumatoid Arthritis, in 2018, a total of 5 million people in China had rheumatoid arthritis. As an ...

New Pharmaceuticals and Healthcare Reports

Publisher: China Research and Intelligence